It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PRME’s FA Score shows that 0 FA rating(s) are green whilePROK’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PRME’s TA Score shows that 4 TA indicator(s) are bullish while PROK’s TA Score has 3 bullish TA indicator(s).
PRME (@Biotechnology) experienced а +0.69% price change this week, while PROK (@Biotechnology) price change was -15.88% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.
PRME is expected to report earnings on Mar 06, 2025.
PROK is expected to report earnings on Apr 01, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
PRME | PROK | PRME / PROK | |
Capitalization | 383M | 196M | 195% |
EBITDA | -207.13M | -131.07M | 158% |
Gain YTD | -67.269 | -15.169 | 443% |
P/E Ratio | N/A | N/A | - |
Revenue | 800K | 0 | - |
Total Cash | 176M | 407M | 43% |
Total Debt | 41.2M | 6.44M | 640% |
PRME | ||
---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 88 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PRME | PROK | |
---|---|---|
RSI ODDS (%) | 3 days ago90% | N/A |
Stochastic ODDS (%) | 3 days ago75% | 3 days ago67% |
Momentum ODDS (%) | 3 days ago87% | 3 days ago58% |
MACD ODDS (%) | 3 days ago84% | 3 days ago66% |
TrendWeek ODDS (%) | 3 days ago81% | 3 days ago63% |
TrendMonth ODDS (%) | 3 days ago85% | 3 days ago67% |
Advances ODDS (%) | 3 days ago76% | 6 days ago72% |
Declines ODDS (%) | 5 days ago87% | 4 days ago77% |
BollingerBands ODDS (%) | 3 days ago72% | 3 days ago56% |
Aroon ODDS (%) | 3 days ago90% | N/A |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ABRWX | 17.80 | 0.28 | +1.60% |
DSS AmericaFirstMonthlyRisk-OnRisk-Off I | |||
ETIHX | 33.68 | 0.48 | +1.45% |
Eventide Healthcare & Life Sciences I | |||
GMYPX | 16.72 | 0.18 | +1.09% |
Goldman Sachs Large Cap Value P | |||
ODIIX | 127.57 | 1.07 | +0.85% |
Invesco Discovery R6 | |||
JHJCX | 22.03 | -1.98 | -8.25% |
JHancock ESG Large Cap Core C |
A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.
Ticker / NAME | Correlation To PRME | 1D Price Change % | ||
---|---|---|---|---|
PRME | 100% | +3.94% | ||
CRSP - PRME | 63% Loosely correlated | +0.83% | ||
BEAM - PRME | 61% Loosely correlated | +8.04% | ||
NTLA - PRME | 59% Loosely correlated | +0.83% | ||
RXRX - PRME | 56% Loosely correlated | -0.99% | ||
ABCL - PRME | 55% Loosely correlated | +5.17% | ||
More |
A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RXRX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RXRX could also see price increases.
Ticker / NAME | Correlation To PROK | 1D Price Change % | ||
---|---|---|---|---|
PROK | 100% | +3.42% | ||
RXRX - PROK | 37% Loosely correlated | -0.99% | ||
PRME - PROK | 34% Loosely correlated | +3.94% | ||
BEAM - PROK | 33% Poorly correlated | +8.04% | ||
ADPT - PROK | 32% Poorly correlated | +6.50% | ||
RNA - PROK | 32% Poorly correlated | +2.48% | ||
More |